帕博利珠单抗联合培美曲塞和铂类化疗对比安慰剂联合化疗治疗酪氨酸激酶抑制剂耐药的EGFR突变转移性非鳞状非小细胞肺癌的III期KEYNOTE-789研究
KEYNOTE-789是一项随机双盲III期研究,纳入492例EGFR-TKI耐药、EGFR突变(DEL19或L858R)的IV期非鳞状非小细胞肺癌患者,1:1随机接受帕博利珠单抗或安慰剂联合培美曲塞和铂类化疗。最终分析显示,帕博利珠单抗联合化疗组中位无进展生存期为5.6个月对比安慰剂联合化疗组5.5个月(HR 0.80,95%CI 0.65-0.97,P=0.0122),中位总生存期为15.9个月对比14.7个月(HR 0.84,95%CI 0.69-1.02,P=0.0362)。结论认为在TKI耐药、EGFR突变转移性非鳞状非小细胞肺癌中,化疗基础上加用帕博利珠单抗对比安慰剂联合化疗未显著延长PFS或OS。
要点
- 帕博利珠单抗联合化疗组中位PFS 5.6个月,安慰剂联合化疗组5.5个月(HR 0.80,95%CI 0.65-0.97,P=0.0122)。
- 帕博利珠单抗联合化疗组中位OS 15.9个月,安慰剂联合化疗组14.7个月(HR 0.84,95%CI 0.69-1.02,P=0.0362)。
- 帕博利珠单抗联合化疗组≥3级治疗相关不良事件发生率43.7%,安慰剂联合化疗组38.6%。
核心结论
- 在TKI耐药、EGFR突变、转移性非鳞状非小细胞肺癌患者中,化疗基础上加用帕博利珠单抗对比安慰剂联合化疗未显著延长PFS或OS。
研究设计与样本
- 随机、双盲、III期KEYNOTE-789研究(ClinicalTrials.gov NCT03515837),纳入病理确诊IV期非鳞状非小细胞肺癌、 documented DEL19或L858R EGFR突变、EGFR-TKI治疗后进展的成人患者。
- 患者1:1随机分配至帕博利珠单抗200 mg每3周一次共35个周期或安慰剂,联合培美曲塞和卡铂或顺铂每3周一次共4个周期,随后培美曲塞维持治疗。
- 双主要终点为无进展生存期(PFS)和总生存期(OS);PFS最终检验在第二次中期分析(IA2,数据截止2021年12月3日)完成,OS在最终分析(FA,数据截止2023年1月17日)检验;PFS和OS的疗效界值均为单侧P=0.0117。
- 共492例患者随机分配至帕博利珠单抗联合化疗组(n=245)或安慰剂联合化疗组(n=247)。
主要发现
- IA2时,帕博利珠单抗联合化疗组中位PFS为5.6个月,安慰剂联合化疗组为5.5个月(HR 0.80,95%CI 0.65-0.97,P=0.0122)。
- FA时,帕博利珠单抗联合化疗组中位OS为15.9个月,安慰剂联合化疗组为14.7个月(HR 0.84,95%CI 0.69-1.02,P=0.0362)。
- 帕博利珠单抗联合化疗组≥3级治疗相关不良事件发生率为43.7%,安慰剂联合化疗组为38.6%。
关键数值与推荐
- PFS的疗效界值为单侧P=0.0117,IA2时帕博利珠单抗联合化疗组对比安慰剂联合化疗组HR 0.80(95%CI 0.65-0.97),P=0.0122。
- OS的疗效界值为单侧P=0.0117,FA时帕博利珠单抗联合化疗组对比安慰剂联合化疗组HR 0.84(95%CI 0.69-1.02),P=0.0362。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR-mutant, metastatic non-small cell lung cancer (NSCLC); however, most patients experience disease progression. We report results from the randomized, double-blind, phase III KEYNOTE-789 study of pemetrexed and platinum-based chemotherapy with or without pembrolizumab for TKI-resistant, EGFR-mutant, metastatic nonsquamous NSCLC (ClinicalTrials.gov identifier: NCT03515837). METHODS: Adults with pathologically confirmed stage IV nonsquamous NSCLC, documented DEL19 or L858R EGFR mutation, and progression after EGFR-TKI treatment were randomly assigned 1:1 to 35 cycles of pembrolizumab 200 mg or placebo once every 3 weeks plus four cycles of pemetrexed and carboplatin or cisplatin once every 3 weeks and then maintenance pemetrexed. Dual primary end points were progression-free survival (PFS) and overall survival (OS). Final PFS testing was completed at the second interim analysis (IA2; data cutoff, December 3, 2021); OS was tested at final analysis (FA; data cutoff, January 17, 2023). Efficacy boundaries were one-sided P = .0117 for PFS and OS. RESULTS: Four hundred ninety-two patients were randomly assigned to pembrolizumab plus chemotherapy (n = 245) or placebo plus chemotherapy (n = 247). At IA2, the median PFS was 5.6 months for pembrolizumab plus chemotherapy versus 5.5 months for placebo plus chemotherapy (hazard ratio [HR], 0.80 [95% CI, 0.65 to 0.97]; P = .0122). At FA, the median OS was 15.9 versus 14.7 months, respectively (HR, 0.84 [95% CI, 0.69 to 1.02]; P = .0362). Grade ≥3 treatment-related adverse events occurred in 43.7% of pembrolizumab plus chemotherapy recipients versus 38.6% of placebo plus chemotherapy recipients. CONCLUSION: Addition of pembrolizumab to chemotherapy in patients with TKI-resistant, EGFR-mutant, metastatic nonsquamous NSCLC did not significantly prolong PFS or OS versus placebo plus chemotherapy in KEYNOTE-789.
引用
- Yang JC, Lee DH, Lee JS, et al. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer. J Clin Oncol. 2024. PMID: 39173098. doi:10.1200/JCO.23.02747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。